NSPRInspireMD, Inc.
- GlobeNewswire
InspireMD Reports Second Quarter 2026 Financial Results
- Company to host investor conference call today, August 17th, at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the ...
- GlobeNewswire
InspireMD to Announce Second Quarter 2026 Financial Results
MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced ...
- GlobeNewswire
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced ...
- GlobeNewswire
InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced ...
- GlobeNewswire
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the ...
- GlobeNewswire
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day ...
- GlobeNewswire
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the ...
- Earnings Call Transcripts
2026 GLOBAL HEALTHCARE CONFERENCEINSPIREMD INC
Good afternoon, everyone. My name is Aidan Leahy. I'm on the MedTech Research Team at Bank of America. Really excited to introduce InspireMD. We'll have Chief Communication Officer Shane Gleason come up to give a present ...
- GlobeNewswire
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to ...
- Analyst Upgrades
Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3
Piper Sandler analyst Adam Maeder reiterates InspireMD with a Overweight and lowers the price target from $4 to $3. ...
- Earnings Call Transcripts
Q1 2026 InspireMD Earnings CallINSPIREMD INC
Good morning and welcome to InspireMD's first quarter 2026 earnings conference call. Currently, all participants are in listen-only mode. We will facilitate a question-and-answer session towards the end of today's call. ...
- GlobeNewswire
InspireMD Reports First Quarter 2026 Financial Results
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro ...
- GlobeNewswire
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. ...
- GlobeNewswire
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% - - FDA approval anticipated with U.S. market availability of ...
- GlobeNewswire
InspireMD to Announce First Quarter 2026 Financial Results
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter ...
- PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)
Purcell & Lefkowitz LLP announces that it is investigating InspireMD, Inc. (NASDAQ: NSPR) on behalf of the company's shareholders. The investigation... ...
- GlobeNewswire
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th ...
- GlobeNewswire
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter ...
- GlobeNewswire
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the ...
- GlobeNewswire
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ...
- GlobeNewswire
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent ...
- GlobeNewswire
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the ...
- GlobeNewswire
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside ...
- GlobeNewswire
InspireMD Reports Third Quarter 2025 Financial Results
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial ...
- GlobeNewswire
InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the ...